UA73276C2 - A humanized antiboby being specifically bonded to the protein of alpha-activation of fibroplasts (fap?). - Google Patents

A humanized antiboby being specifically bonded to the protein of alpha-activation of fibroplasts (fap?). Download PDF

Info

Publication number
UA73276C2
UA73276C2 UA2000116786A UA2000116786A UA73276C2 UA 73276 C2 UA73276 C2 UA 73276C2 UA 2000116786 A UA2000116786 A UA 2000116786A UA 2000116786 A UA2000116786 A UA 2000116786A UA 73276 C2 UA73276 C2 UA 73276C2
Authority
UA
Ukraine
Prior art keywords
bek
antibody
cells
human
mai
Prior art date
Application number
UA2000116786A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UA73276C2 publication Critical patent/UA73276C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
UA2000116786A 1998-04-30 1999-04-22 A humanized antiboby being specifically bonded to the protein of alpha-activation of fibroplasts (fap?). UA73276C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98107925A EP0953639A1 (en) 1998-04-30 1998-04-30 FAPalpha-specific antibody with improved producibility
PCT/EP1999/002711 WO1999057151A2 (en) 1998-04-30 1999-04-22 FAP α-SPECIFIC ANTIBODY WITH IMPROVED PRODUCIBILITY

Publications (1)

Publication Number Publication Date
UA73276C2 true UA73276C2 (en) 2005-07-15

Family

ID=8231860

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000116786A UA73276C2 (en) 1998-04-30 1999-04-22 A humanized antiboby being specifically bonded to the protein of alpha-activation of fibroplasts (fap?).

Country Status (27)

Country Link
EP (2) EP0953639A1 (pl)
JP (1) JP4421779B2 (pl)
KR (1) KR100580936B1 (pl)
CN (1) CN1303430A (pl)
AR (1) AR016243A1 (pl)
AT (1) ATE356873T1 (pl)
AU (1) AU760305B2 (pl)
BG (1) BG65034B1 (pl)
BR (1) BR9910577A (pl)
CA (1) CA2327586C (pl)
CO (1) CO5050255A1 (pl)
DE (1) DE69935516T2 (pl)
EA (1) EA005401B1 (pl)
EE (1) EE200000642A (pl)
ES (1) ES2283114T3 (pl)
HU (1) HUP0101501A3 (pl)
ID (1) ID26555A (pl)
IL (1) IL138701A0 (pl)
NO (1) NO20005412L (pl)
NZ (1) NZ508456A (pl)
PL (1) PL358087A1 (pl)
SK (1) SK16192000A3 (pl)
TR (1) TR200003181T2 (pl)
UA (1) UA73276C2 (pl)
WO (1) WO1999057151A2 (pl)
YU (1) YU66300A (pl)
ZA (1) ZA200005506B (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118496382A (zh) * 2024-05-22 2024-08-16 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
AU2001256325A1 (en) * 2000-03-17 2001-09-24 Boehringer Ingelheim Pharma Kg Human and humanized fap-alpha-specific antibodies
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
JP2005530856A (ja) * 2002-06-21 2005-10-13 ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 膜関連腫瘍内皮マーカー
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
BRPI0407487A (pt) * 2003-02-14 2006-02-14 Biogen Idec Inc cassete e um vetor de expressão para a expressão transitória ou estável de moléculas exógenas
MXPA06012601A (es) 2004-05-10 2007-05-10 Macrogenics Inc Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
SI2573114T1 (sl) 2005-08-10 2016-08-31 Macrogenics, Inc. Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
WO2007059782A1 (en) * 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US7776331B1 (en) 2007-01-16 2010-08-17 Abbott Laboratories Methods of treating plaque psoriasis
NZ580379A (en) 2007-03-29 2012-10-26 Abbott Lab Crystalline anti-human il-12 antibodies
EP2185591B1 (en) * 2007-08-20 2014-05-14 Glaxo Group Limited Production method
KR101202220B1 (ko) * 2007-12-10 2012-11-16 에프. 호프만-라 로슈 아게 암 마커로서의 세프라아제
WO2009074276A2 (en) * 2007-12-10 2009-06-18 Roche Diagnostics Gmbh Marker panel for colorectal cancer
EP2071337A1 (en) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase as a marker for cancer
TWI461210B (zh) 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
CA2720365C (en) 2008-04-02 2019-01-15 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
MX2012003138A (es) 2009-09-14 2012-07-04 Abbott Lab Y Abbott Gmbh & Co Kg Metodos para tratar la psoriasis.
CA2776385C (en) 2009-10-07 2019-04-09 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EA034742B1 (ru) 2010-08-13 2020-03-16 Роше Гликарт Аг Антитела к fap, полинуклеотид, вектор и клетка для их получения и их применения
BR112013005699B1 (pt) 2010-09-09 2021-08-17 Pfizer Inc Anticorpo isolado ou porção de ligação ao antígeno do mesmo que se liga ao 4-1bb humano, combinação, usos dos mesmos, bem como composição farmacêutica, molécula de ácido nucleico isolada e vetor
LT3075745T (lt) 2011-02-10 2018-11-26 Roche Glycart Ag Mutavę interleukino-2 polipeptidai
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
HUE047398T2 (hu) * 2014-03-26 2020-04-28 Univ Wuerzburg J Maximilians Növekedési és differenciálódási faktor 15 (GDF-15) elleni monoklonális antitestek és azok alkalmazásai rákos sorvadás és rák kezelésére
CN105646710B (zh) * 2014-11-17 2020-08-25 四川科伦博泰生物医药股份有限公司 一种全人源化抗vegfr-2单克隆抗体及其制备方法
MY198560A (en) 2015-10-02 2023-09-05 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
WO2017132617A1 (en) * 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
PE20190353A1 (es) 2016-04-15 2019-03-07 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN116474108A (zh) * 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
CN110526979A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
CN110526991A (zh) * 2018-05-25 2019-12-03 深圳宾德生物技术有限公司 靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
CN109053893B (zh) * 2018-08-15 2021-03-30 智享生物(苏州)有限公司 一种抗d-二聚体单克隆抗体及其制备方法
CN110882385B (zh) * 2018-09-07 2021-07-09 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗肿瘤中的用途
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
DK3997103T3 (da) 2019-07-08 2024-12-02 3B Pharmaceuticals Gmbh Forbindelser med fibroplast-aktiverende proteinligand og anvendelse deraf
IL324399A (en) 2019-07-08 2026-01-01 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4026846A4 (en) * 2019-09-03 2023-09-13 Bio-Thera Solutions, Ltd. Anti-tigit immunosuppressant and application thereof
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
KR102363980B1 (ko) * 2020-04-13 2022-02-15 전남대학교산학협력단 전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
EP4143239A4 (en) * 2020-04-30 2024-10-02 I-Mab Biopharma Co., Ltd. PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES
PH12022553153A1 (en) 2020-05-19 2024-02-26 Boehringer Ingelheim Int Binding molecules for the treatment of cancer
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
KR102784691B1 (ko) * 2020-08-11 2025-03-25 주식회사 카나프테라퓨틱스 Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도
CA3206863A1 (en) 2021-01-07 2022-07-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
WO2023031644A1 (en) 2021-08-31 2023-03-09 Full-Life Technologies Limited Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof
EP4457346A1 (en) * 2021-12-30 2024-11-06 Concept to Medicine Biotech Co., Ltd. Human antibodies against fap-alpha
EP4578877A1 (en) 2022-08-03 2025-07-02 Nanjing Leads Biolabs Co., Ltd. Antibody fusion protein targeting fap and tgf-beta, and use thereof
US20260053923A1 (en) 2022-10-07 2026-02-26 Genethon Immunotherapy of Skeletal Myopathies Using ANTI-FAP CAR-T Cells
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
WO2025152756A1 (zh) * 2024-01-15 2025-07-24 迈威(上海)生物科技股份有限公司 重组抗fap抗体及其应用
CN118812715A (zh) * 2024-07-02 2024-10-22 国睿(广州)生物科技有限公司 一种靶向成纤维活化蛋白α的纳米抗体及其应用
CN119265201A (zh) * 2024-08-23 2025-01-07 中国人民解放军海军军医大学第一附属医院 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU2782292A (en) * 1991-09-18 1993-04-27 Sloan-Kettering Institute For Cancer Research Activated stromal fibroblast-specific antibody, f19 and methods of using the same
ZA936260B (en) * 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
DK1143006T3 (da) * 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
IL126121A0 (en) * 1996-05-01 1999-05-09 Genitope Corp Vaccines for treatment of lymphoma and leukemia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118496382A (zh) * 2024-05-22 2024-08-16 山东第一医科大学附属省立医院(山东省立医院) 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用

Also Published As

Publication number Publication date
ZA200005506B (en) 2002-05-14
SK16192000A3 (sk) 2001-04-09
EA200001023A1 (ru) 2001-06-25
DE69935516D1 (de) 2007-04-26
WO1999057151A3 (en) 2000-03-16
NO20005412L (no) 2000-12-06
EP0953639A1 (en) 1999-11-03
EP1098979B1 (en) 2007-03-14
CA2327586C (en) 2013-02-26
ID26555A (id) 2001-01-18
ES2283114T3 (es) 2007-10-16
IL138701A0 (en) 2001-10-31
TR200003181T2 (tr) 2001-04-20
PL358087A1 (pl) 2004-08-09
EA005401B1 (ru) 2005-02-24
NO20005412D0 (no) 2000-10-27
JP4421779B2 (ja) 2010-02-24
BG65034B1 (bg) 2006-12-29
HUP0101501A3 (en) 2004-01-28
ATE356873T1 (de) 2007-04-15
CA2327586A1 (en) 1999-11-11
AU760305B2 (en) 2003-05-15
JP2002513556A (ja) 2002-05-14
KR20010042826A (ko) 2001-05-25
EE200000642A (et) 2002-04-15
AU4032299A (en) 1999-11-23
AR016243A1 (es) 2001-06-20
CO5050255A1 (es) 2001-06-27
CN1303430A (zh) 2001-07-11
KR100580936B1 (ko) 2006-05-17
DE69935516T2 (de) 2008-01-31
WO1999057151A2 (en) 1999-11-11
BR9910577A (pt) 2001-09-11
BG104828A (en) 2001-09-28
EP1098979A2 (en) 2001-05-16
NZ508456A (en) 2004-03-26
YU66300A (sh) 2004-03-12
HUP0101501A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
UA73276C2 (en) A humanized antiboby being specifically bonded to the protein of alpha-activation of fibroplasts (fap?).
US8697065B2 (en) Non-natural ribonuclease conjugates as cytotoxic agents
EP1575484B1 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
JP4932883B2 (ja) 血管系の特異的凝固のための方法および組成物
US6506883B2 (en) Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
US5489525A (en) Monoclonal antibodies to prostate cells
ES2277341T3 (es) Anticuerpo bioespecifico para tratar el linfoma de linfocitos b y linea celular.
HU211881A9 (en) Recombinant antibodies for human therapy
AU2076995A (en) Antibodies against e-selectin
WO2016112855A1 (zh) 抗cd19单克隆抗体及其制备方法
KR20220012856A (ko) 항 ｐｄ―ｌ１ 항체 및 그의 용도
WO2021052307A1 (zh) 一种抗b7-h3抗体及其应用
JP2005507373A (ja) カテプシンｂ活性を中和するモノクロナール抗体及びその使用
Morrison et al. Genetically engineered antibody molecules: new tools for cancer therapy
KR101442323B1 (ko) 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
CA2481829A1 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
MXPA06005540A (es) Anticuerpo del receptor anti-igf-i.
WO2022142272A1 (zh) Cldn18.2抗体及其应用
WO1993010221A1 (en) Chimeric murine/human anti-idiotype monoclonal antibodies
AU2013201832A1 (en) Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
HK1134099A (en) Anti-angiogenic compounds
TW200526682A (en) Laminin-5γ2-binding peptides, related compositions, and use thereof
JPWO2001023431A1 (ja) ガングリオシドｇｍ２に対する抗体の誘導体
CZ20004032A3 (cs) Zdokonalená produkce protilátek specifických pro FAP-alfa